Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients
Journal of Clinical Medicine · 05.08.2024 · 13 (15) · 4559
DOI: 10.3390/jcm13154559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.08.2024. Verfasst von Selene Nicolosi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Allergology and Immunology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dupilumab is a monoclonal antibody used for the treatment of moderate/severe atopic dermatitis (AD). In recent years, several studies have confirmed the positive association between AD and overweight/obesity, and a report demonstrated the effect of weight reduction on the improvement of AD symptoms.
Methods
The weight of 170 patients under treatment with dupilumab was recorded at baseline and after 48 weeks (T48). Clinical monitoring was mainly conducted using the Eczema Area and Severity Index (EASI). The study aimed to assess a possible correlation between the clinical outcome of dupilumab therapy and BMI.
Results
Although not statistically significant, patients with a BMI < 25 have a higher EASI percentage improvement than patients with a BMI ≥ 25 at any time point, and the percentage of overweight and obese patients that does not reach EASI-75 at T48 is higher compared to normal-weight patients (13.5% vs. 5.9%). Despite this, in the multivariate regression analysis, no baseline characteristic, including BMI, appears to increase the risk of not reaching EASI-75. In addition, the results show no differences in BMI between baseline and T48 in any age/sex group.
Conclusions
The results suggest that overweight and obese patients have a lower response to dupilumab when considering the EASI score, but this difference does not appear to be clinically significant. Furthermore, dupilumab treatment does not seem to impact weight.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Allergology and Immunology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
- Independent Researcher, 23900 Lecco, Italy.
- Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, 20122 Milan, Italy.
ORCID-Profile: Maurizio Romagnuolo, Angelo Valerio Marzano, Silvia Mariel Ferrucci
Zitieren
APA
Nicolosi, S., Barei, F., Romagnuolo, M., Fumagalli, S., Marzano, A. V., & Ferrucci, S. M. (2024). Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients. Journal of Clinical Medicine, 13(15), 4559. https://doi.org/10.3390/jcm13154559
Vancouver
Nicolosi S, Barei F, Romagnuolo M, Fumagalli S, Marzano AV, Ferrucci SM. Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients. Journal of Clinical Medicine. 2024;13(15):4559. doi:10.3390/jcm13154559
BibTeX
@article{Nicolosi2024,
author = {Nicolosi, Selene and Barei, Francesca and Romagnuolo, Maurizio and Fumagalli, Silvio and Marzano, Angelo Valerio and Ferrucci, Silvia Mariel},
title = {Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {15},
pages = {4559},
doi = {10.3390/jcm13154559}
}
EUVIMED